[{"id":"b630115d-34b5-4a22-8fda-e1bacb84ad3e","acronym":"STOMP","url":"https://clinicaltrials.gov/study/NCT03004183","created_at":"2021-01-18T14:46:41.242Z","updated_at":"2025-02-25T16:05:38.291Z","phase":"Phase 2","brief_title":"SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC","source_id_and_acronym":"NCT03004183 - STOMP","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ProstAtak (aglatimagene besadenovec) • valacyclovir"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 07/22/2022","primary_completion_date":" 07/22/2022","study_txt":" Completion: 01/09/2024","study_completion_date":" 01/09/2024","last_update_posted":"2024-10-15"},{"id":"11fe933c-a4d6-496a-a112-e60b2e4b87c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03313596","created_at":"2021-01-18T16:21:54.363Z","updated_at":"2024-07-02T16:37:03.209Z","phase":"Phase 3","brief_title":"Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC","source_id_and_acronym":"NCT03313596","lead_sponsor":"Huazhong University of Science and Technology","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ProstAtak (aglatimagene besadenovec)"],"overall_status":"Unknown status","enrollment":" Enrollment 180","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-02-04"}]